Predictive Oncology Inc. articles
This white paper details a study by Predictive Oncology and UPMC Magee-Womens Hospital. By combining the assets and domain expertise of both organizations, this collaboration aimed to improve ovarian cancer prognosis and treatment through accurate patient stratification and survival outcome predictions.
Background and objective
High grade serous carcinoma (HGSC) of the ovary is a complex and deadly disease. Although frontline treatment of chemotherapy and surgery
Oncology drug development makes up almost half of the annual R&D expenditure of biopharmaceutical companies. Only 10% of drugs advanced to the clinical stage are successfully brought to market, with half of all failures attributed to lack of clinical efficacy. This means that approximately $60 billion dollars are spent annually on unsuccessful drugs.1,2
Contributing to these unchecked costs - and the complexity of drug discovery and development - is the fact that the typical timel
Population growth, aging populations and increases in cancer incidence have necessitated new approaches to identifying effective treatments.
One such approach involves the repositioning, or repurposing, of drugs already FDA approved in either non-oncology disease states and/or approved in a limited number of tumor types. The repurposing of these drugs for new indications represents an opportunity to circumvent the time and investment that must go into the discovery, d
Many oncology drugs have been abandoned by pharmaceutical companies due to poor performance in phase I, II, or III clinical trials.
These drugs represent untapped potential treatments for indications outside of those initially investigated. With research and development costs for a single new drug estimated between $2–3 billion, abandoned drugs represent an opportunity to bring drugs to market for new tumor indications at a fraction of the cost (approximately $3